These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2576139)

  • 21. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine.
    Lorens SA; Hata N; Cabrera T; Hamilton ME
    NIDA Res Monogr; 1989; 95():347. PubMed ID: 2577039
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of (+-)3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats.
    Matthews RT; Champney TH; Frye GD
    Pharmacol Biochem Behav; 1989 Aug; 33(4):741-7. PubMed ID: 2575758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA).
    Lowy MT; Nash JF; Meltzer HY
    Eur J Pharmacol; 1989 Apr; 163(1):157-61. PubMed ID: 2472965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine.
    Zacny JP; Virus RM; Woolverton WL
    Pharmacol Biochem Behav; 1990 Mar; 35(3):637-42. PubMed ID: 1971112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin contributes to the spinal antinociceptive effects of morphine.
    Crisp T; Stafinsky JL; Uram M; Perni VC; Weaver MF; Spanos LJ
    Pharmacol Biochem Behav; 1991 Jul; 39(3):591-5. PubMed ID: 1686100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens.
    Nash JF; Meltzer HY; Gudelsky GA
    J Neurochem; 1990 Mar; 54(3):1062-7. PubMed ID: 1689375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylenedioxymethamphetamine induces spontaneous tail-flicks in the rat via 5-HT1A receptors.
    Millan MJ; Colpaert FC
    Eur J Pharmacol; 1991 Feb; 193(2):145-52. PubMed ID: 1675609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.
    Nader MA; Hoffmann SM; Barrett JE
    Psychopharmacology (Berl); 1989; 98(2):183-8. PubMed ID: 2569215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
    Steele TD; Nichols DE; Yim GK
    Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examination of spinal monoamine receptors through which brainstem opiate-sensitive systems act in the rat.
    Jensen TS; Yaksh TL
    Brain Res; 1986 Jan; 363(1):114-27. PubMed ID: 3004638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain.
    Ricaurte GA; Finnegan KF; Nichols DE; DeLanney LE; Irwin I; Langston JW
    Eur J Pharmacol; 1987 Jun; 137(2-3):265-8. PubMed ID: 2886355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrathecal coadministration of clonidine with serotonin receptor agonists produces supra-additive visceral antinociception in the rat.
    Danzebrink RM; Gebhart GF
    Brain Res; 1991 Jul; 555(1):35-42. PubMed ID: 1933328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (+/-)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Eur J Pharmacol; 1989 Oct; 169(1):11-21. PubMed ID: 2574685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE; "EVE").
    Boja JW; Schechter MD
    Pharmacol Biochem Behav; 1987 Oct; 28(2):153-6. PubMed ID: 2891144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDMA as a discriminative stimulus: isomeric comparisons.
    Schechter MD
    Pharmacol Biochem Behav; 1987 May; 27(1):41-4. PubMed ID: 2886996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discriminative stimulus properties of (+/-)-3,4-methylenedioxymethamphetamine and (+/-)-3,4-methylenedioxyamphetamine in pigeons.
    Evans SM; Johanson CE
    Drug Alcohol Depend; 1986 Oct; 18(2):159-64. PubMed ID: 2877843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.
    Stone DM; Stahl DC; Hanson GR; Gibb JW
    Eur J Pharmacol; 1986 Aug; 128(1-2):41-8. PubMed ID: 2875893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats.
    Li AA; Marek GJ; Vosmer G; Seiden LS
    Pharmacol Biochem Behav; 1989 Jul; 33(3):641-8. PubMed ID: 2573905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis.
    Nash JF
    Life Sci; 1990; 47(26):2401-8. PubMed ID: 1979830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.